These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 19118710

  • 1. Pharmacokinetics.
    Byeon SH, Kang SY.
    Ophthalmology; 2009 Jan; 116(1):168-9; author reply 169-70. PubMed ID: 19118710
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ.
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of intravitreal bevacizumab (Avastin).
    Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ.
    Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA.
    Retina; 2007 May; 27(9):1260-6. PubMed ID: 18046235
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
    Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
    [Abstract] [Full Text] [Related]

  • 6. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
    Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B.
    Retina; 2009 May; 29(5):699-703. PubMed ID: 19430280
    [Abstract] [Full Text] [Related]

  • 7. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
    Krohne TU, Eter N, Holz FG, Meyer CH.
    Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
    [Abstract] [Full Text] [Related]

  • 8. Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit.
    Kim MJ, Han ES, Kim J, Kim TW.
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):49-53. PubMed ID: 20148650
    [Abstract] [Full Text] [Related]

  • 9. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
    Meyer CH, Krohne TU, Holz FG.
    Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
    [Abstract] [Full Text] [Related]

  • 10. Predicted biologic activity of intravitreal bevacizumab.
    Stewart MW.
    Retina; 2007 Feb; 27(9):1196-200. PubMed ID: 18046224
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
    la Cour M.
    Acta Ophthalmol Scand; 2007 Feb; 85(1):2-4. PubMed ID: 17244202
    [No Abstract] [Full Text] [Related]

  • 12. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V.
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T.
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
    [Abstract] [Full Text] [Related]

  • 14. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S.
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [Abstract] [Full Text] [Related]

  • 15. The pharmacokinetics of rituximab following an intravitreal injection.
    Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Grillo-Lopez AJ, Wilson WH, Robinson MR.
    Exp Eye Res; 2006 May; 82(5):760-6. PubMed ID: 16289160
    [Abstract] [Full Text] [Related]

  • 16. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
    Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.
    Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
    Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, Lichtlen P, Urech DM.
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
    [Abstract] [Full Text] [Related]

  • 18. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
    Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM.
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):779-86. PubMed ID: 18757511
    [Abstract] [Full Text] [Related]

  • 19. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.
    Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M.
    Invest Ophthalmol Vis Sci; 2012 Aug 24; 53(9):5877-80. PubMed ID: 22836776
    [Abstract] [Full Text] [Related]

  • 20. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans.
    Meyer CH, Krohne TU, Holz FG.
    Retina; 2011 Oct 24; 31(9):1877-84. PubMed ID: 21738089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.